RxDoctor Payments DataLook up a doctor →

Saulius Kalvaitis, MD

Clinical Cardiac Electrophysiology · Saint Louis, MONPI 1023218278

Payments from drug & device makers

$88,836in general payments, 2019–2025

Across 959 payments — averaging $92.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$62K
  • Medical Device Business Services, Inc.$6K
  • Atricure, Inc.$5K
  • Biosense Webster, Inc.$4K
  • Abbott$3K
  • Novartis$2K
  • plus $7K from 35 others

What the payments were for

  • Consulting fees$9,60022%
  • Speaking & faculty fees$4,0009%
  • Travel & lodging$15,64936%
  • Food & beverage$13,99032%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,836 in reported general payments places this provider in the 75th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$348,924
Medicare patients
583
Services billed
5,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban413$495,773
XareltoRivaroxaban156$168,986
AdempasRiociguat12$164,681
EntrestoSacubitril/Valsartan129$150,195
Dofetilide481$109,531
JardianceEmpagliflozin55$72,868
Repatha SureclickEvolocumab25$21,221
FarxigaDapagliflozin Propanediol18$20,944
OzempicSemaglutide15$16,482
Diltiazem Hcl261$9,374
Diltiazem 24hr Er (Cd)Diltiazem Hcl101$7,039
VerquvoVericiguat11$7,038
VascepaIcosapent Ethyl16$5,725
Dabigatran EtexilateDabigatran Etexilate Mesylate12$5,690
Flecainide Acetate120$5,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$353$495,773413 claims
Johnson & JohnsonXarelto$476$168,986156 claims
BayerAdempas$955$164,68112 claims
NovartisEntresto$1,813$150,195129 claims
Boehringer IngelheimJardiance$443$72,86855 claims
AstraZenecaFarxiga$511$20,94418 claims
Novo NordiskOzempic$36$16,48215 claims
MerckVerquvo$424$7,03811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →